{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:11:10Z","timestamp":1761235870348},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China led to a public health emergency of international concern, putting all health organizations on high alert in the beginning of 2020. Corona virus disease 2019 (COVID-19) is highly infectious and has resulted in thousands of deaths which exceeded that of the SARS coronavirus (SARS-CoV) outbreak back in 2002 and 2003 in China. Besides, the number of diagnosed patients, patients who are suspected to have contracted the disease, and deaths are increasing worldwide. Unfortunately, effective drugs and vaccines to combat SARS-CoV-2 are still lacking. Convalescent plasma, a seemingly successful treatment for COVID-19 patients, proved to be of huge value in terms of saving severely ill patients. This review introduces the reported effects, potential mechanisms, and future uncertainties of convalescent plasma therapy in the treatment of COVID-19 patients, in the hopes that it will provide useful information for relevant physicians and researchers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bs9.0000000000000047","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T21:02:00Z","timestamp":1604955720000},"page":"71-75","source":"Crossref","is-referenced-by-count":7,"title":["Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19"],"prefix":"10.1097","volume":"2","author":[{"given":"Weiqian","family":"Dai","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihui","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Changhai Hospital , The Second Military Medical University, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Hao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"(5)","key":"R2-20230726","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"(9)","key":"R3-20230726","first-page":"e343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS One"},{"issue":"(9)","key":"R4-20230726","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"(2)","key":"R5-20230726","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"(3)","key":"R6-20230726","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/dkn243","article-title":"The management of coronavirus infections with particular reference to SARS","volume":"62","author":"Wong","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R7-20230726","first-page":"93","article-title":"Convalescent serum and pooled plasma in communicable diseases","volume":"46","author":"Rambar","year":"1946","journal-title":"US Nav Med Bull"},{"issue":"(2)","key":"R8-20230726","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus"},{"issue":"(2)","key":"R9-20230726","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.transci.2014.10.003","article-title":"Ebola virus convalescent blood products: where we are now and where we may need to go","volume":"51","author":"Burnouf","year":"2014","journal-title":"Transfus Apher Sci"},{"issue":"(5)","key":"R10-20230726","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"issue":"(1)","key":"R11-20230726","first-page":"1","article-title":"Neutralization mechanism of a highly potent antibody against Zika virus","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat Commun"},{"key":"R12-20230726","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies","volume":"24","author":"Corti","year":"2017","journal-title":"Curr Opin Virol"},{"issue":"(6288)","key":"R13-20230726","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"issue":"(12)","key":"R14-20230726","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.4049\/jimmunol.166.12.7381","article-title":"Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections","volume":"166","author":"Huber","year":"2001","journal-title":"J Immunol"},{"issue":"(1)","key":"R15-20230726","first-page":"1","article-title":"Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice","volume":"8","author":"He","year":"2017","journal-title":"Nat Commun"},{"issue":"(13)","key":"R16-20230726","article-title":"Fc functional antibodies in humans with severe H7N9 and seasonal influenza","volume":"2","author":"Vanderven","year":"2017","journal-title":"JCI Insight"},{"issue":"(4)","key":"R17-20230726","article-title":"Influenza-specific antibody-dependent phagocytosis","volume":"11","author":"Ana-Sosa-Batiz","year":"2016","journal-title":"PLoS One"},{"issue":"(6279)","key":"R18-20230726","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"R19-20230726","article-title":"Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"issue":"(42)","key":"R20-20230726","doi-asserted-by":"crossref","first-page":"11931","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"He","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"R21-20230726","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"Van Erp","year":"2019","journal-title":"Front Immunol"},{"issue":"(8)","key":"R22-20230726","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"issue":"(1)","key":"R23-20230726","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"issue":"(7)","key":"R24-20230726","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"(12)","key":"R25-20230726","first-page":"1018","article-title":"Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area","volume":"83","author":"Zhou","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"(14)","key":"R26-20230726","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"issue":"(4)","key":"R27-20230726","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"(3)","key":"R28-20230726","first-page":"39","article-title":"Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention","volume":"54","author":"Cracoviensia","year":"2014","journal-title":"Folia Med Cracov"},{"issue":"(1)","key":"R29-20230726","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"Van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"(1)","key":"R30-20230726","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R31-20230726","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"(4)","key":"R32-20230726","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States","volume":"61","author":"Kraft","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R35-20230726","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-4690-8-16","article-title":"Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection","volume":"8","author":"Willey","year":"2011","journal-title":"Retrovirology"},{"issue":"(24)","key":"R36-20230726","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.vaccine.2007.12.028","article-title":"Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development","volume":"26","author":"Beck","year":"2008","journal-title":"Vaccine"},{"issue":"(5)","key":"R37-20230726","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-enhancing antibodies to Ebola virus glycoprotein","volume":"75","author":"Takada","year":"2001","journal-title":"J Virol"},{"issue":"(13)","key":"R38-20230726","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","article-title":"Antibody-dependent enhancement of Ebola virus infection","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"issue":"(5)","key":"R39-20230726","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"(5)","key":"R40-20230726","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"R42-20230726","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"(4)","key":"R43-20230726","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3343\/alm.2016.36.4.393","article-title":"Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome","volume":"36","author":"Chun","year":"2016","journal-title":"Ann Lab Med"},{"issue":"(17)","key":"R44-20230726","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2018-10-860809","article-title":"Transfusion-associated circulatory overload and transfusion-related acute lung injury","volume":"133","author":"Semple","year":"2019","journal-title":"Blood"},{"issue":"(2)","key":"R46-20230726","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2009.06.003","article-title":"IgM in microbial infections: taken for granted?","volume":"125","author":"Racine","year":"2009","journal-title":"Immunol Lett"},{"key":"R47-20230726","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijid.2020.03.065","article-title":"Diagnostic value and dynamic variance of serum antibody in coronavirus disease","volume":"94","author":"Jin","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"(1)","key":"R48-20230726","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"issue":"(6)","key":"R49-20230726","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","article-title":"Structural basis for human coronavirus attachment to sialic acid receptors","volume":"26","author":"Tortorici","year":"2019","journal-title":"Nat Struct Mol Biol"},{"issue":"(2)","key":"R50-20230726","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"(1)","key":"R51-20230726","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"}],"container-title":["Blood Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T10:25:39Z","timestamp":1690367139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bs9.0000000000000047","relation":{},"ISSN":["2543-6368"],"issn-type":[{"value":"2543-6368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}